| Filed On | Filing |
|---|---|
| 08 Sep 2026 |
8-K: Other Events
Executive Director, Investor Relations and Corporate Communications |
| 17 Aug 2026 |
Form 4: Barnette K Gary, Chief Scientific Officer
Bought 1,800 shares ($4.84K) |
| 10 Aug 2026 | FORM 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Executive Director, Investor Relations and Corporate Communications |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Veru Inc., a Wisconsin corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) and Canaccord Genuity LLC (“Canaccord” and, together with Oppenheimer, the “Agents” and each an “Ag... |
| 02 Jul 2026 | 424B5 |
| 04 Jun 2026 |
8-K: Other Events
On June 2, 2026, Veru Inc. (the “Company”) entered into a clinical supply agreement (the “Supply Agreement”) with Novo Nordisk A/S (“Novo Nordisk”) in conjunction with the Company’s Phase 2b PLATEAU clinical study.* The objective of the ... |
| 13 May 2026 | FORM S-8 |
| 13 May 2026 | FORM 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Executive Director, Investor Relations and Corporate Communications |
| 06 May 2026 |
Form 4: Steiner Mitchell Shuster, Director
Granted 604,000 Common Stock Option |
| 06 May 2026 |
Form 4: Greco Michele, Chief Admin Officer and CFO
Granted 164,000 Common Stock Option |
| 06 May 2026 |
Form 4: Katzovitz Loren Mark, Director
Granted 102,000 Common Stock Option |
| 06 May 2026 |
Form 4: Hyun Grace, Director
Granted 97,000 Common Stock Option |
| 06 May 2026 |
Form 4: Rankowitz Michael L, Director
Granted 100,000 Common Stock Option |
| 06 May 2026 |
Form 4: Lu Lucy, Director
Granted 104,000 Common Stock Option |
| 06 May 2026 |
Form 4: Barnette K Gary, Chief Scientific Officer
Granted 160,000 Common Stock Option |
| 06 May 2026 |
Form 4: Fisch Harry, Director
Granted 160,000 Common Stock Option |
| 15 Apr 2026 | EFFECT |
| 15 Apr 2026 | EFFECT |
Loading...